IN ACTIVE PSORIATIC ARTHRITISStart and Stay With a Choice of Administration Options for STELARA® (ustekinumab)

Dosing

  • The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks1
  • For patients with coexistent moderate to severe plaque psoriasis weighing >220 lbs, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks1

Two dosage forms help meet the needs of patients

STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up visits. Patients may self-inject with STELARA® after physician approval and proper training. Patients should be instructed to follow the direction provided in the Medication Guide.

Dosing Comparison

Dosing of commonly used biologic treatments in PsA— total number of doses in first 52 weeks of therapy

STELARA®
(ustekinumab):

Once every 12 weeks
(after 2 starter doses at Weeks 0 and 4)1

Just 4 maintenance
doses per year!

Enbrel®
(etanercept):

Once every week2

CIMZIA®
(certolizumab pegol):

Once every other week
after 3 starter doses at
Weeks 0, 2, and 43*

Humira®
(adalimumab):

Once every other week4

Cosentyx®
(secukinumab):

Once every 4 weeks
(after once-weekly
dosing for the
first 5 doses)5

TALTZ®
(ixekizumab):

Once every 4 weeks
after 2
80-mg injections
at Week 06

This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to the full Prescribing Information of each agent for dosage and administration. All trademarks are property of their respective owners.

*The recommended dose of Cimzia® for adult patients with PsA is 400 mg (given as 2 subQ injections of 200 mg each) initially and at Weeks 2 and 4, followed by 200 mg every other week. For maintenance dosing, Cimzia® 400 mg every 4 weeks can be considered.3

For patients with PsA with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis. The recommended dosage is 300 mg by subQ injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300-mg dose is given as subQ injections of 150 mg. For some patients, a dose of 150 mg may be acceptable.4

 

For patients with PsA, administer Cosentyx® with or without a loading dose by subQ injection. The recommended dosage:

  • With a loading dose is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter4
  • Without a loading dose is 150 mg every 4 weeks4
  • If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks. Cosentyx® may be administered with or without MTX4
 

References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Pharmaceuticals, Inc. 2. Enbrel® [package insert]. Thousand Oaks, CA: Immunex Corp; 2019. 3. Cimzia® [package insert]. Smyrna, GA: UCB, Inc; 2019. 4. Humira® [package insert]. North Chicago, IL: AbbVie Inc; 2019. 5. Cosentyx® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2018. 6. Taltz® [package insert]. Indianapolis, IN: Eli Lilly and Company, 2019.

close tooltip
Cimzia® (certolizumab pegol) Indication

Cimzia® is indicated for the treatment of adult patients with active PsA.3

close tooltip
Taltz® (ixekizumab) Indication

Taltz® is indicated for the treatment of adult patients with active PsA.6

close tooltip
Cosentyx® (secukinumab) Indication

Cosentyx® is indicated for the treatment of adult patients with active psoriatic arthritis.4

close tooltip
Otezla® (apremilast) Indication, tablets for oral use

Otezla® is indicated for the treatment of adult patients with active psoriatic arthritis.5

close tooltip
Humira® (adalimumab) Indication

Humira® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. Humira® can be used alone or in combination with nonbiologic DMARDs.4

close tooltip
Cosentyx® (secukinumab) Indication

Cosentyx® is indicated for the treatment of adult patients with active PsA.5

close tooltip
Otezla® (apremilast) Indication, tablets for oral use

Otezla® is indicated for the treatment of adult patients with active psoriatic arthritis.5

close tooltip
Enbrel® (etanercept) Indication

Enbrel® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with PsA. Enbrel® can be used with or without MTX.2